Subscriptions

Advertising

Resources

About Us

Contact Us

Create An Account Forgot Your Password?
Trouble logging in or creating an account? click here
Home This Month E-Weekly Newsletter Building a Facility Article Archive Second Opinions
Search:
Benchmarking
General Surgery
Accrediting/Quality
Anesthesia
Code/Bill/Reimburse
Building/Renovating
/_media/adv/web/images/2010/20100824_HCA_LB_154x100.gif
/_media/adv/web/images/2010/20100511_Arthrex_LB_154x100.gif
/_media/adv/web/images/2010/20100407_ORX_LB-01_154x100.gif
Outpatient Surgery E-Weekly

OR Excellence Pre-Registration Ends Wednesday

This Wednesday, Sept. 1, is your last chance to participate in Outpatient Surgery Magazine's OR Excellence 2010 Pre-Registration Contest. There's no...

Researchers Predict Anesthesiologist Shortage, CRNA Surplus

A recent analysis of the anesthesia labor market speculates that a current shortfall of providers across the surgical industry could widen in the ne...

A Change of Mind: Anesthesia, Consciousness and the Brain

The brain works through different processes as it transitions between conscious and unconscious states, a finding that bucks commonly held assumptio...

Home > News > October, 2009

FDA: Congressional Pressure Influenced Approval of Knee Repair Device

Report criticizes "unprecedented" exertion of interest by 4 lawmakers on behalf of ReGen.

Food and Drug Administration officials acknowledged in a report late last month that "extreme" pressure from federal lawmakers influenced the agency's decision to approve a knee repair device in December 2008.

Four New Jersey Democrats — Reps. Frank Pallone and Steve Rothman and Sens. Robert Menendez and Frank Lautenberg — who reportedly received a combined $26,000 in campaign donations from Hackensack, N.J.-based ReGen Biologics, intervened on behalf of the company and its collagen scaffold device for knee repair, Menaflex, according to the FDA report. The agency's scientists had twice rejected the device, saying it did not provide a significant benefit to patients.

The agency's investigation found that former FDA Commissioner Andrew von Eschenbach, after urging from the 4 lawmakers, became directly involved in the case, agreeing to a meeting with ReGen executives, after which he told FDA staffers to "follow the science" when making a decision on Menaflex, according to an AP report.

"In the ReGen review, unusual perhaps unprecedented Congressional interest, the degree of senior agency official participation, and an aggressive company all exerted significant pressures on a complicated system of submission review," the FDA report concludes. The agency says it's re-evaluating the decision to approve Menaflex but has no plans to take it off the market. AP reports that the device has generated more than $700,000 in sales for ReGen since its approval last year. Efforts to reach ReGen for comment were unsuccessful.

Meanwhile, agency leaders are calling for a better system of handling contentious issues between companies and FDA staff. "The stronger our underlying process is, the less likely it will be interfered with," says FDA Principal Deputy Commissioner Joshua Sharfstein, MD.

Irene Tsikitas

Categories: Legal/Regulatory, Product Reports, News
Already have an account? Please sign in:
Email Address:
Password:
PRODUCT & SERVICE RESOURCES
Product & Service Showcase
A showcase of products and services geared to make your facility better.
Professional Services Platinum Pages
A guide of people and companies to help make your facility better.
Other Articles That May Interest You
How Confidential Is Your Accreditation Survey?
Under court order, Joint Commission releases site visit info to federal investigators.
This Just In
Do You Facebook?
Ill. Officials Seek to Close ASC Owned by Convicted Sex Offender
Chicago doc convicted of sexually abusing a patient continues to practice.